Treatment of canine atopic dermatitis with intravenously administered autologous bone marrow

This entry is article 4 of 7 in the February 2015 issue

Atopic dermatitis (AD) also known as atopic eczema, affects approximately 10% of dogs worldwide and is likely the most prevalent canine skin diseases requiring medical intervention. Current treatment options for dogs afflicted with this condition include antihistamines, corticosteroids, cyclosporine A, oclacitinib, and allergen-specific immunotherapy (ASIT) administered subcutaneously or sublingually, as well as adjunctive treatments such as topical and systemic antimicrobial therapy. It is difficult to avoid allergens in many cases.. Certain issues may arise with treatment options due to possible unreliable,therapeutic methods that may have adverse reactions, or come with significant financial burden. There is a great need for finding a novel, safe, and effective treatment for the management of canine atopic dermatitis.

Multipotent mesenchymal stem cells (MSCs) have been extensively evaluated in human medicine for their clinical applications in the repair of damaged tissues and in the treatment of chronic, degenerative inflammatory diseases because of their diverse wound healing and anti-inflammatory properties.

Our primary goal is to investigate the effectiveness of autologous Bone Marrow MSCs (BM-MSCs) in easing the clinical signs associated with canine AD and the safety of BM-MSCs given that no prior safety study has been performed at our hospital. Our secondary goal is to investigate the feasibility of this protocol for future applications in larger scale randomized controlled double-blinded clinical trials.

For more information regarding this study, please visit:

Series Navigation